Optometry 360
  • Home
  • Conferences
  • Videos
  • About Us
    • About Us – Mission
    • Media Partners
    • Advisory Board
    • Industry Council
    • Business Team

What are you looking for?

  • Conference Roundup
  • Contact Lenses
  • Diagnostics
  • Glaucoma
  • Myopia
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Retina
  • Spotlight Series
Navigating Presbyopia Conversations with Patients in Practice
Optometry 360
  • Home
  • Conferences
  • Videos
  • About Us
    • About Us – Mission
    • Media Partners
    • Advisory Board
    • Industry Council
    • Business Team
Home > Incorporating biomarker testing into ocular surface disease management to improve patient outcomes
  • Ocular Surface Disease

Incorporating biomarker testing into ocular surface disease management to improve patient outcomes

Optometry 360

In part 1 of a 2-part video series, Brandon Ayres, MD, and Nicole Fram, MD, discuss why eye care providers should take a more comprehensive, proactive approach to ocular surface disease by looking beyond corneal staining to identify underlying causes, particularly early neurotrophic keratitis (NK), and intervene before the cornea deteriorates. Incorporating routine corneal sensitivity testing, MMP-9, and tear osmolarity measurements can help identify at-risk patients, distinguish disease etiologies, and guide more targeted treatment rather than relying on generalized dry eye therapies.

Question:

Your recent peer-reviewed paper highlights the importance of identifying neurotrophic keratitis earlier in the disease process. What lessons from that work can ophthalmologists apply to their broader approach to evaluating ocular surface disease?

Brandon Ayres, MD:

It’s a great question and there’s a lot to it. Traditionally, people have just looked at corneal staining and labeled almost all ocular surface disease dry eye, but we know that there’s a lot of different components to ocular surface disease. The focus of our paper was looking at patients with clinical and subclinical NK in that spectrum of ocular surface disease and looking for patients who may have had we’ll say a cornea at risk, maybe they had some mild, moderate, or even severe corneal sensation reduction as well as corneal staining and risk factors like diabetes, prior refractive surgery, and also looking at biomarkers, in particular MMP-9 and tear film osmolarity. By trying to look globally at the picture of what’s going on on the ocular surface, treat those patients.

These were all what would be considered stage 1 NK patients, no official epithelial defect, but they did have corneal staining and some level of reduced sensation according to Brill esthesiometry or risk factors for NK. Taking all those factors together, then treating with serial decellularized basement membrane to see if we could reduce staining and improve biomarkers, taking those patients with I’ll call it early NK or stage 1 NK, but then protecting that cornea and showed improvement in corneal staining as well as improvement in biomarkers and improvement in corneal sensation. It’s really trying to take a much more global look, a bigger picture look at dry eye or ocular surface disease, screen for patients at risk for or with stage 1 NK, and then being very proactive in that treatment to make sure that those patients don’t progress.

Nicole Fram, MD:

I fully agree with Brandon’s assessment of our paper, but really how do you know if these patients need treatment? Often what you’ll see are these signs, these subclinical NK patients will have heaped up epithelium. Sometimes they’ll have a whorl keratopathy, and it’s really vision quality that these patients can present with. It’s not necessarily they’re having a physical complaint because they have some neurotrophic status. These patients can be chronic contact lens wearers. These can be patients that you’re screening for refractive surgery. The idea of having a treatment regimen that isn’t just preservative-free artificial drops or a mild steroid drop treatment that may not get to the root of the issue, having a procedure that you can repeat at least maybe one to three times to get that corneal surface more regularized and to improve the corneal sensation, I think was most impactful from the study.

Question:

Today, we have access to several objective diagnostic tools, including MMP-9 testing, tear osmolarity, corneal staining, and corneal sensitivity testing. How do you incorporate these biomarkers into your routine workup, and what unique information does each provide?

Brandon Ayres, MD:

Looking at biomarkers really allows you to take a deep dive into what’s going on the ocular surface. This is how we are trying to separate what the etiology is for that ocular surface disease. Checking corneal sensation, I mean that basically just shows what is the neurosensory unit doing, how’s the subbasal nerve plexus in its health, because that nerve reflex loop is very, very important for ocular health. Then you’re also looking at tear film osmolarity, and that has been shown in multiple papers to be a very sensitive indicator for ocular surface disease and a surrogate for inflammation. Then looking at MMP-9 is actually a direct look at the inflammatory status of the cornea. When you put those factors all together, it really does help you identify a cornea at risk for problems.

Maybe it’s an ocular surface problem with fluctuating vision or complaints, burning, stinging, irritation, whatever it may be, or maybe it’s a cornea at risk for breakdown after surgery, whether it’s laser refractive, cataract surgery, corneal surgery, or contact lens intolerance. But incorporating that additional information into your workflow isn’t that difficult. Most of these are point-of-care tests. Using something like the Brill esthesiometer is a non-contact test, and it gives you so much more information as to what’s going on on that ocular surface. It helps us screen out patients or screen inpatients with stage 1 or more neurotrophic keratitis so that we can get them to a targeted treatment as opposed to a very generalized stepwise treatment.

Meaning first we’ll add some tears of warm compresses and then we’ll add an anti-inflammatory and then we’ll add this or that. When we’re getting all this information all at once, we can go direct to the source, identify the etiology of the problem and go to what may have been previously seen as a more advanced or late stage treatment and bring it in right away as a first line treatment.

Nicole Fram, MD:

I would say that the hardest part is changing the culture of your practice. If you are a practice that runs, runs, runs, and then everyone’s dilated and you see them after dilation, you’re not going to necessarily have all this information and these point of service testing that’s going to help us figure out the inflammatory markers that are increased in your dry eye or NK patients. First step is changing the culture that any patient that has dry eye or has any ocular surface complaints, there are no drops. What’s wonderful about all the point-of-service testing that Brandon mentioned is that you don’t necessarily have to disrupt the corneal surface to get them. The most important point is to make a protocol and change the culture because since we’ve done that in our practice, we’ve been able to utilize so much more information and just like Brandon said, we’re able to direct the therapy more accurately.

Brandon Ayres, MD:

Something I would add, and Nicole, I’m at 100% agreement, we’ve had a very difficult time changing culture and trying to figure out who gets what and when. I think it’s helpful when this just becomes basically this is how we treat every patient because what we have found is that you really don’t know who’s coming in with a problem. We, for the most part, would say if we’re going to screen, we’re going to screen everybody and not try and pick one particular person out looking for problems. It’s amazing what we find when you start looking a little bit deeper into the ocular surface. I really appreciate what you commented about that culture change and how you can incorporate it into the practice.

Question:

Corneal staining has long been a cornerstone of ocular surface evaluation, but why is it no longer enough on its own? What role does corneal sensitivity testing play in helping clinicians identify patients who may otherwise be overlooked?

Nicole Fram, MD:

I think that corneal staining is a wonderful way to understand what the problems are in particular with the patient, whether they have interpalpebral staining, whether they have inferior lid lag and have exposure keratitis, your treatment regimen is going to be different, but being able to identify exactly what kind of corneal staining may happen with NK is really going to help direct your therapy. This idea of this heaped up epithelium, this early NK or even a whorl keratopathy that’s happening has been the most impactful sign for me to realize that I need to either bring the patient back and test again if they’ve already been dilated or see them for the first time when we changed the culture and made sure that we identified the patient before drops.

Corneal staining alone is not enough. Corneal sensitivity is something that really needs to be part of your examination. If you train your technicians to be able to use this, whether or not they’re using the Brill or whether they use a Q-tip that they pull out and then they can check corneal sensation, whatever it is, however you do it, you will be more successful in treating the ocular surface when you incorporate that into practice.

Brandon Ayres, MD:

Couldn’t agree more, Nicole. Corneal staining by itself is the end result of a variety of etiologies of ocular surface disease that all end up affecting the cornea. If you’re only looking at staining, and yes, we can split it into what does the staining look like? Is it inferior? Is it superior? How coarse is it? Is there an epithelial ridge? But it’s still just staining. When you see that stain, you have to go back and try and say, why is that stain here? What is the underlying source of the problem? Instead of lumping everything together as just corneal stain, now we’re going to split and say, okay, there’s staining, why? That’s where the incorporation of the point-of-care test comes.

Once we say, okay, this is why this patient has corneal staining, then we can do our targeted therapies. I don’t think staining is enough because we need more information so that we can tell where the issue is so we know what to treat. Maybe the patient needs lid surgery because they have lagophthalmos, maybe they’ve got an inflammatory condition, maybe it’s neurotrophic, maybe it’s fill in the blank. We want to know what that maybe is so that we can treat. Going back to our paper, that’s why we were trying to find patients who were neurotrophic or had risk factors for neurotrophic keratitis so we could go right to a targeted treatment using decellularized basement membranes.

Share

Related Content

  • Ocular Surface Disease

Check the labels: products containing vitamin A can carry a risk of ocular adverse effects and MGD

  • Conference Roundup

How to have meaningful conversations with patients about holistic management of their glaucoma

  • Conference Roundup

Affects dry eye can have on patients’ quality of life and more highlights from Academy 2026

  • Conference Roundup

Advances in glaucoma: a case-based session

  • Conference Roundup

Why you should be talking to your patients in perimenopause about presbyopia

  • Presbyopia

How to integrate presbyopia care into your practice

Share

Advisory Board

Kaleb Abbott, OD, MS, FAAO

Clark Chang, OD

Jessica Haynes, OD, FAAO, FORS, Dipl ABO

Monica Kalia, OD

Cecelia Koetting, OD, FAAO, DipABO

Roya Attar, OD, MBA, DHA, FAAO

Hardeep Kataria, OD, FAAO

Marc R. Bloomenstein, OD, FAAO

Elise Kramer, OD

See All
Optometry 360

Optometry 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

© 2026 Optometry 360 is a trademark of International Healthcare Media, LLC. All rights Reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophthalmology360 Icon